James Gladden, MD
Interventional Cardiology · Mobile, ALNPI 1861831067
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Edwards Lifesciences at 37.8% of the total. Reporting peaked in 2024 at $2,598 and has fallen 77.5% since, to $584 in 2025.
Across 114 payments — averaging $79.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$3K
- Medtronic$632
- Boston Scientific$356
- Siemens Medical Solutions USA, Inc.$307
- GE HealthCare$252
- plus $1K from 19 others
What the payments were for
- Travel & lodging$4,40349%
- Food & beverage$4,34148%
- Education$2803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 18 | $3,409 |
| Abbott | 26 | $2,872 |
| Medtronic | 9 | $632 |
| Boston Scientific | 4 | $356 |
| Siemens Medical Solutions USA, Inc. | 2 | $307 |
| GE HealthCare | 2 | $252 |
| Pfizer | 12 | $198 |
| Inari Medical, Inc. | 1 | $188 |
| E.r. Squibb & Sons, L.L.C. | 10 | $161 |
| Abiomed | 1 | $111 |
| Novartis | 5 | $81 |
| Novo Nordisk | 3 | $74 |
| Angiodynamics, Inc. | 3 | $66 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $52 |
| Atricure, Inc. | 2 | $49 |
| Boehringer Ingelheim | 2 | $35 |
| Chiesi USA, Inc. | 2 | $33 |
| Biosense Webster, Inc. | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $22 |
| Amgen | 1 | $19 |
| Merck | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Terumo Medical Corporation | 1 | $15 |
| Cardiovascular Systems Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$1,462
- MitraClip$1,220
- Edwards SAPIEN 3 Transcatheter Heart Valve$552
- Resolute$280
- FLOWTRIEVER CATHETER, S$188
- CT THROMBECTOMY SYSTEM KIT$188
- ACUSON Origin Diagnostic Ultrasound System$171
- AMPLATZER AMULET$168
- COREVALVE EVOLUT R$147
- ELUVIA$140
- Artis icono floor$136
- COROFLOW$126
- Impella$111
- WATCHMAN Access System$110
How this compares
$9,024 in reported general payments places this provider in the 60th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 199 | $146,440 |
| EliquisApixaban | 160 | $130,757 |
| EntrestoSacubitril/Valsartan | 102 | $89,953 |
| XareltoRivaroxaban | 37 | $31,917 |
| Repatha SureclickEvolocumab | 16 | $18,092 |
| FarxigaDapagliflozin Propanediol | 22 | $15,055 |
| Ranolazine ErRanolazine | 171 | $14,877 |
| Praluent PenAlirocumab | 13 | $7,472 |
| LivaloPitavastatin Calcium | 11 | $3,543 |
| Rosuvastatin Calcium | 172 | $2,726 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 214 | $2,445 |
| Ezetimibe | 67 | $2,016 |
| Atorvastatin Calcium | 170 | $1,720 |
| Metoprolol Succinate | 129 | $1,480 |
| ClopidogrelClopidogrel Bisulfate | 110 | $1,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $35 | $146,440199 claims |
| PfizerEliquis | $198 | $130,757160 claims |
| NovartisEntresto | $81 | $89,953102 claims |
| AstraZenecaFarxiga | $15 | $15,05522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Mobile
- John GallaMobile$82K
- Ahmed SubahiMobile$37K
- Mir HashimiMobile$24K
- Mohammed ElzeneiniMobile$23K
- Benjamin CitrinMobile$11K
- Stanley ThorntonMobile$7K
- Michael MonsonMobile$7K
- Kevin DeandradeMobile$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.